Trigger 9: Deciphering Developmental Disorder study Flashcards

(45 cards)

1
Q

objective of DDD study

A

understand the genetics architecture of DD

  • catalyse improvement in diagnosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

DDD study is a

A

UK-wide collaborative study with DD families, NHS and the sanger institute

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

DDD strategy

A
  • Systematic clinical phenotyping
  • Exome sequencing and microarrays
  • Feedback
  • Likely genetic diagnoses
  • Share data widely
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

how many families involved

A

13,500

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

clinical data taken

A

age, sex, family history, quantitative data (weight/height etc) and phenotypes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what are used to find CNVs

A

microarrays of the proband

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

proband

A

a person servicing a the starting point of the genetic study of a family

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

which microarray is used

A

2m-prbe array CGH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

exome sequencing used to detect

A

SNVs/ indwells - all of axons plus some regulatory regions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

the study diversity if representative of the UK clinical population

A
  • mostly 0-16
  • diverse ancestry, 5% consanguinity
  • severe undiagnosed DD
  • wide range of phenotypes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

before the study many participants were

A

undiagnosed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what had most participants had before the study

A

clinical microarray 1+ targeted genetic test (55%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

why is family trip exome sequencing useful for diagnosing DDs

A
  • Exclusion of benign inherited variants
  • Finding de novo variants
  • Determining if recessive variants in child are inherited from carrier parents
  • Finding new disease genes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

trio analysis

A

exome sequencing of an affected probing and their unaffected parents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

trio analysis is

A

expensive £1760-2200 (dependent on whether the whole genome or just rare disease genome is sequenced

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

important issues for discussion during consent process

A
  • capacity for consent/assent - likelihood of finding a diagnosis - timescale for finding a diagnosis - potential for treatment - implications for other family members - importance of data sharing - potential for incidental findings o parent not related as expected o health related (adult onset, carrier status etc) o policy on feedback
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

genetic data from child and both parents hugely reduces

A

the number of candidate causal variants

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

two approaches to variant analysis

A

translation and research

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

translation- approach to variant analysis

A

-conservative approach - likely pathogenic variants in published DD genes

20
Q

translation approach involves

A

reporting to clinician for evaluation

21
Q

translation results are

A

shared publicly via DECIPHER database

22
Q

Research- approach to variant analysis

A
  • statistical approach (rigorous) - new genes, complex variants and novel analysis
23
Q

if both parents have healthy allele but child has mutation..

A

due to de novo dominant mutation

24
Q

if both parents have healthy allele but child has mutation, what is the risk of their second child having the mutation

25
if both parents are N/n, what is the risk of inheriting the disease
75% - draw out
26
if both parents are N/n, , what the risk of inheriting in an autosomal dominant fashion (Nn)
50%
27
if both parents are N/n, , what s the risk of inheriting the disease in an autosomal recessive manor
25%
28
if the disease is X-linked and the mother is N/n what is the likelihood of the son getting the disease allele
50%
29
how can we prove that a novel variant i a previously uncharacterised gene causes a monogenic disease like DD
1. Find other similar patients with similar variants in the same gene 2. Show unaffected individuals do not carry similar variants in same gene 3. Test segregation in family members and other affected families 4. Use functional studies to show effect of variant 5. Use statistical methods to show enrichment of variants in disease cohort
30
enrichment analysis
s a method to identify classes of genes or proteins that are over-represented in a large set of genes or proteins, and may have an association with disease phenotypes.
31
there are statistical tests of enrichment for
damaging de novo mutations for every gene in the genome
32
how does enrichment analysis work
The method uses statistical approaches to identify significantly enriched or depleted groups of genes
33
enrichment analysis graph
statistical test of enrichment of damaging de novo mutations for every gene in the genome
34
sequence mutations increase with
paternal and maternal age
35
parental age effect is mostly due to
replication errors in mitosis
36
mutations caused by parent age are mostly due to
replication errors in mitosis
37
paternal age effect
single gene defects e.g. can relate to birthweight, congenital disorders, life expectancy, and psychological outcomes
38
maternal age effect causes
structural mutations - mostly due to recombination errors in meiosis I - evidenced by obsereved trisomies
39
diagnostic yield of the DDD study
around 40% - mostly (70%) de novo mutations - mostly thanks to new gene discovery
40
Coffin-Siris syndrome caused by
caused by de novo loss of function mutations ARID1B
41
ARID1b
is a chromatin remodeller (changes DNA accessibility for gene expression)
42
phenotypic spectrum of Coffin-Siris (ARID1b)
Developmental delay, speech delay, abnormalities in pinky finger or toes, short sighted, feeding difficulties Overlaps with other disorders
43
treatment for Coffin-Siris (ARID1b) syndrome
no treatment- parents can be genetically counselled on the recurrence risk
44
how can more DD be found
To find more DD genes- we need more samples… Options: 1. Recruit more patients (not possible with DDD!) 2. Persuade other researchers to give us their data (i.e. collaborate with other similar cohorts) 3. Share our data with other researches - openly or managed access - ethical framework required
45
why can it often be challenging to find a diagnosis?
Enormous amount of genetic variation Every genome contains novel variation Most genetic variation is benign Phenotypic and genetic heterogeneity Disease inheritance and mechanism may be unknown Phenotypes may have more than one genetic cause